Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
10,694
datasets available to search
ShareScore release 0.9.0
Dataset results
10,694 results for “carcinoma,”
Hematoxylin-and-eosin-stained bladder urothelial cell carcinoma versus inflammation digital histopathology image dataset
Open the record for dataset details and reuse information.
Data from: Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma
Open the record for dataset details and reuse information.
Data from: CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma
Open the record for dataset details and reuse information.
Data from: Neoadjuvant and concurrent chemotherapy have varied impacts on the prognosis of patients with the ascending and descending types of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
Open the record for dataset details and reuse information.
Database for high-risk nasopharyngeal carcinoma treated with chemoradiotherapy and immunotherapy
Open the record for dataset details and reuse information.
Protein expression of hepatocellular carcinoma in a fibrotic liver in mice
Open the record for dataset details and reuse information.
Data from: In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma
Open the record for dataset details and reuse information.
Data from: Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data
Open the record for dataset details and reuse information.
Data from: Reduced CTGF Expression Promotes Cell Growth, Migration, and Invasion in Nasopharyngeal Carcinoma
Open the record for dataset details and reuse information.
New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin
Open the record for dataset details and reuse information.
Clinical and histopathological features of 81 cases of canine apocrine gland carcinoma of the anal sac
Open the record for dataset details and reuse information.
Data from: Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation
<p class="AbstractSummary"><b>Background</b></p> <p class="AbstractSummary">Prostate cancer (PC) is the most frequently diagnosed cancer in North American men. Pathologists are in critical need of accurate biomarkers to characterize PC, particularly to confirm the presence of intraductal carcinoma of the prostate (IDC-P), an aggressive histopathological variant for which therapeutic options are now available. Our aim was to identify IDC-P with Raman micro-spectroscopy and machine learning technology following a protocol suitable for routine clinical histopathology laboratories.</p> <p class="AbstractSummary"><b>Methods and findings</b></p> <p class="AbstractSummary">We used Raman micro-spectroscopy to differentiate IDC-P from PC, as well as PC and IDC-P from benign tissue on formalin-fixed paraffin-embedded first-line radical prostatectomy specimens (embedded in tissue microarrays, TMAs) from 483 patients treated in three Canadian institutions between 1993 and 2013. The main measures were the presence or absence of IDC-P and of PC, regardless of the clinical outcomes. Most of the 483 patients were pT2 stage (44–69%), and pT3a (22–49%) was more frequent than pT3b (9–12%). After approval of the construction of the TMAs by local ethics review board, the diagnostic accuracy study was approved by the Centre hospitalier de l'Université de Montréal (CHUM) ethics review board. Briefly, two consecutive sections of each TMA block were cut. The first section was transferred onto a glass slide to perform immunohistochemistry with H&E counterstaining for cell identification. The second section was placed on an aluminum slide, dewaxed, and then used to acquire an average of 7 Raman spectra per specimen (between 4 and 24 Raman spectra, 4 acquisitions / TMA core). Raman spectra of each cell type were then analyzed to retrieve tissue-specific molecular information and to generate classification models using machine learning technology. <span>Models were trained and cross-validated using data from one institution. Accuracy, sensitivity and specificity were respectively of 87 ± 5%, 86 ± 6% and 89 ± 8% to differentiate PC from benign tissue, and of 95 ± 2%, 96 ± 4% and 94 ± 2% respectively to differentiate IDC-P from PC. The trained models were then tested on data from two independent institutions, reaching accuracies, sensitivities and specificities of 84 and 86%, 84 and 87%, and 81 and 82%, respectively</span><span> to diagnose PC, and of 85 and 91%, 85 and 88%, and 86 and 93% respectively for the identification of IDC-P.</span> IDC-P could further be differentiated from high-grade prostatic intraepithelial neoplasia (HGPIN), a pre-malignant intraductal proliferation which can be mistaken as IDC-P, with accuracies, sensitivities and specificities >95% in both training and testing cohorts. As we used stringent criteria to diagnose IDC-P, the main limitation of our study is the exclusion of borderline, difficult to classify lesions from our datasets.</p> <p class="AbstractSummary"><b>Conclusions</b></p> <p>In this study, we developed classification models for the analysis of Raman micro-spectroscopy data to differentiate IDC-P, PC and benign tissue, including HGPIN. Raman micro-spectroscopy could be a next-generation histopathological technique used to <span>reinforce the identification of high-risk PC patients and lead to more precise diagnosis of IDC-P.</span></p>
Data from: Downregulation of endometrial mesenchymal marker SUSD2 causes cell senescence and cell death in endometrial carcinoma cells
The cause of death among the majority of endometrial cancer patients involves migration of cancer cells within the peritoneal cavity and subsequent implantation of cancer spheroids into neighbouring organs. It is, thereby, important to identify factors that mediate metastasis. Cell adhesion and migration are modified by the mesenchymal stem cell (MSC) marker Sushi domain containing 2 (SUSD2), a type I transmembrane protein that participates in the orchestration of cell adhesion and migration through interaction with its partner Galactosidase-binding soluble-1 (LGALS1). MSCs have emerged as attractive targets in cancer therapy. Human endometrial adenocarcinoma (Ishikawa) cells were treated with TGFβ (10ng/ml) for 72h. SUSD2, LGALS1 and MKI67 transcript levels were quantified using qRT-PCR. The proportion of SUSD2 positive (SUSD2+) cells and SMAD2/3 abundance were quantified by FACS and Western blotting, respectively. Senescent cells were identified with β-galactosidase staining; cell cycle and cell death were quantified using Propidium Iodide staining. Treatment of endometrial cancer cells (Ishikawa cells) with TGFβ (10ng/ml) significantly decreased SUSD2 transcript levels and the proportion of SUSD2 positive cells. Silencing of SUSD2 using siRNA resulted in senescence and cell death of Ishikawa cells via activation of SMAD2/3. These findings suggest that SUSD2 counteracts senescence and cell death and is thus a potential chemotherapeutic target in human endometrial cancer.
Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma – knowledge obtained from the CheckRad-CD8 trial
<p>Raw cell counts from peripheral blood immune phenotyping across individual patients.</p>
Esterase- responsive SLC7A11 shRNA Delivery System Induced Ferroptosis and Suppressed Hepatocellular Carcinoma Progression
Open the record for dataset details and reuse information.
Figure 10 from: Al-Sahlawi F, Al-Ani I, El-Tanani M, Farooq HA (2024) Preparation and evaluation of biological activity of ZSM-5 nanoparticles loaded with gefitinib for the treatment of non-small cell lung carcinoma. Pharmacia 71: 1-12. https://doi.org/10.3897/pharmacia.71.e112449
Figure 10 Normalize of transform of A. ZSM-5 Carrier only; B. Free GEF, and C. GEF-ZSM-5 loaded prepared by kneading method (ratio 1:1).
Figure 7 from: Al-Sahlawi F, Al-Ani I, El-Tanani M, Farooq HA (2024) Preparation and evaluation of biological activity of ZSM-5 nanoparticles loaded with gefitinib for the treatment of non-small cell lung carcinoma. Pharmacia 71: 1-12. https://doi.org/10.3897/pharmacia.71.e112449
Figure 7 Drug release profile of free GEF and GEF from the loaded NPs for 60 min, phosphate buffer pH 6.8, apparatus II (paddle), 50 rpm, and 37 °C.
Figure 11 from: Al-Sahlawi F, Al-Ani I, El-Tanani M, Farooq HA (2024) Preparation and evaluation of biological activity of ZSM-5 nanoparticles loaded with gefitinib for the treatment of non-small cell lung carcinoma. Pharmacia 71: 1-12. https://doi.org/10.3897/pharmacia.71.e112449
Figure 11 Control migration testing Treatment of A-549 cells with: Half-Maximal Inhibitory Concentration (IC50), IC50, 2 IC50, Double-Maximal.
Figure 8 from: Al-Sahlawi F, Al-Ani I, El-Tanani M, Farooq HA (2024) Preparation and evaluation of biological activity of ZSM-5 nanoparticles loaded with gefitinib for the treatment of non-small cell lung carcinoma. Pharmacia 71: 1-12. https://doi.org/10.3897/pharmacia.71.e112449
Figure 8 Drug release profile of free GEF and GEF from the loaded NPs for 12 hr, phosphate buffer pH 6.8, apparatus II(paddle), 50 rpm, and 37 °C.
Figure 12 from: Al-Sahlawi F, Al-Ani I, El-Tanani M, Farooq HA (2024) Preparation and evaluation of biological activity of ZSM-5 nanoparticles loaded with gefitinib for the treatment of non-small cell lung carcinoma. Pharmacia 71: 1-12. https://doi.org/10.3897/pharmacia.71.e112449
Figure 12 Colony test of untreated A-549 cells in a control. utilizing free gefitinib and ZSM- 5-gefitinib-loaded utilizing kneading technique 1:1 w/w, 12 IC50 stands for half dosage of the half maximum inhibitory concentration, IC50 for the half maximum inhibitory concentration, and 2 IC50 for double dose of the half maximum inhibitory concentration. Comparisons between each dosage and the control were made. The findings were shown as mean SD. The signs for statistical significance were *P 0.05, **P 0.01, and ***P 0.001.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.